Polyserase-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Polyserase-2 (PRSS36; UniProt Q5K4E3), produced in HEK293 cells. Suitable for serine protease activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-Polyserase2

In stock

SKU
REC-Polyserase2
$498.00

Target Overview

Polyserase-2 (gene: PRSS36; UniProt Q5K4E3) is a secreted, extracellular serine protease belonging to the polyserase family. The full-length human protein spans 855 amino acids and is localised to the extracellular space and extracellular matrix. This recombinant form is produced in HEK293 mammalian cells, providing post-translational processing — including glycosylation — that is relevant to the native secreted protein and to assays where proper folding and disulfide-bond formation are required for activity. Biochemically, Polyserase-2 preferentially hydrolyses fluorogenic peptide substrates carrying an Arg residue at the P1 position: it cleaves N-t-Boc-Gln-Ala-Arg-AMC and N-t-Boc-Gln-Gly-Arg-AMC with higher efficiency than the corresponding Lys-containing substrates N-t-Boc-Ala-Phe-Lys-AMC and N-t-Boc-Val-Leu-Lys-AMC. This defined substrate preference makes the recombinant protein well-suited for fluorometric activity assays, kinetic parameter determination (Km, kcat), and serine-protease inhibitor IC50 measurements using AMC-releasing peptide substrates. In addition to enzymatic studies, this recombinant serves as a validated positive-control antigen for Western blot and immunohistochemistry-based antibody characterisation. Researchers requiring both the recombinant protein and a matched detection reagent can pair this product with the Triple Point Biologics Polyserase-2 antibody (SKU: RP-Polyserase2), which is cross-referenced on this page. The HEK293 expression system is appropriate for studies in which native-like glycoforms or secretory signal processing may influence protein behaviour in binding or activity experiments.

Background

Polyserase-2 (PRSS36) is a member of the polyserase subfamily of trypsin-fold serine proteases — a structurally distinctive group characterised by the presence of multiple serine protease domains encoded within a single polypeptide precursor. The protein is secreted into the extracellular space and extracellular matrix, positioning it to act on extracellular substrates and potentially influence pericellular proteolytic cascades. Its substrate specificity, with a marked preference for Arg over Lys at the P1 position, is consistent with a trypsin-like catalytic mechanism. The biological roles of Polyserase-2 remain an active area of investigation. Genetically, PRSS36 has attracted attention through human genetic and multi-omics approaches. A 2024 Mendelian randomisation study (Guo X et al., Sci Rep, 2024; PMID 39397091) identified PRSS36 as a candidate research target in psoriasis, alongside the established TYK2 locus, using genetically proxied protein abundance as an instrument. Separately, integrative multi-omics analyses investigating myasthenia gravis have detected PRSS36 signals in immune-cell-specific expression datasets (Li J et al., J Transl Med, 2024; PMID 38521921), suggesting a potential role in immune tissue contexts — though the mechanistic basis remains to be defined in functional experiments. PRSS36 locus variants have also appeared in epigenome-wide studies examining cord blood DNA methylation in response to environmental exposures (Alfano R et al., Environ Res, 2023; PMID 36400229), indicating that PRSS36 expression may be subject to epigenetic regulation in early development. In oncology-related research, mutational profiling of pseudomyxoma peritonei of ovarian origin identified PRSS36 among the mutated genes in that rare malignancy (Wang B et al., Int J Cancer, 2021; PMID 33403690), providing a rationale for characterising the protease in tumour-associated extracellular matrix remodelling studies. Taken together, published literature positions Polyserase-2 as a research target across dermatological, immunological, and oncological study areas. The recombinant protein described here provides a defined enzymatic tool for in vitro characterisation of PRSS36 activity, inhibitor identification, and antibody validation. Researchers can pair this reagent with the Triple Point Biologics matched antibody (RP-Polyserase2), validated for Western blot, to support both functional and localisation studies in the same experimental programme.

Applications

  • Fluorometric serine protease activity assay using N-t-Boc-Gln-Ala-Arg-AMC or N-t-Boc-Gln-Gly-Arg-AMC substrates
  • Kinetic parameter determination (Km, Vmax, kcat) for Arg-P1 fluorogenic peptide substrates
  • Small-molecule serine protease inhibitor IC50 profiling and selectivity counterscreening
  • Antibody validation positive control for Western blot — pairs with Triple Point Biologics RP-Polyserase2
  • Immunohistochemistry antibody validation standard using recombinant protein spotted on nitrocellulose or tissue-surrogate sections
  • Substrate specificity profiling by comparing Arg-P1 versus Lys-P1 AMC-peptide cleavage rates
  • Biophysical binding studies (SPR, ITC) to characterise interaction with candidate extracellular inhibitors or binding partners
  • Recombinant antigen for ELISA standard curve construction and assay development

References

  1. Guo X et al. Validation of TYK2 and exploration of PRSS36 as drug targets for psoriasis using Mendelian randomization. Sci Rep. 2024. doi:10.1038/s41598-024-74148-3. PMID: 39397091.
  2. Ouyang Y et al. Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis. Hum Genomics. 2024. doi:10.1186/s40246-024-00607-7. PMID: 38659056.
  3. Li J et al. Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis. J Transl Med. 2024. doi:10.1186/s12967-024-04994-2. PMID: 38521921.
  4. Alfano R et al. Epigenome-wide analysis of maternal exposure to green space during gestation and cord blood DNA methylation in the ENVIRONAGE cohort. Environ Res. 2023. doi:10.1016/j.envres.2022.114828. PMID: 36400229.
  5. Wang B et al. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary. Int J Cancer. 2021. doi:10.1002/ijc.33460. PMID: 33403690.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight should I expect for recombinant Polyserase-2 on SDS-PAGE or Western blot?

The full-length human Polyserase-2 (PRSS36, UniProt Q5K4E3) is 855 amino acids, giving a predicted polypeptide molecular weight of approximately 95 kDa. Because this recombinant is produced in HEK293 cells, N-linked glycosylation adds additional mass; the apparent MW on reducing SDS-PAGE typically runs higher, often in the 110–130 kDa range depending on gel conditions and glycosylation extent. If you are comparing to a bacterially expressed standard, expect a meaningful upward shift. Under non-reducing conditions, disulfide-mediated dimers may also be visible.

Which isoform or processing form of Polyserase-2 does this recombinant represent — full-length or a domain fragment?

This product represents the secreted, full-length human Polyserase-2 (855 aa, PRSS36). The native protein is processed post-translationally: the signal peptide is removed upon secretion, and the catalytic serine protease domain is retained in the mature form. Production in HEK293 cells allows proper signal-peptide cleavage and disulfide-bond formation, so the recombinant closely mirrors the extracellular, matrix-associated species you would detect in conditioned medium or ECM fractions. If your experimental model involves intracellular forms, this product is not the appropriate reference.

What fluorogenic substrates work best for a Polyserase-2 activity assay?

Polyserase-2 preferentially cleaves substrates carrying Arg at the P1 position. The two highest-efficiency fluorogenic substrates are N-t-Boc-Gln-Ala-Arg-AMC and N-t-Boc-Gln-Gly-Arg-AMC. Both yield significantly greater fluorescent signal per unit time than the corresponding Lys-P1 substrates (N-t-Boc-Ala-Phe-Lys-AMC and N-t-Boc-Val-Leu-Lys-AMC). For initial activity verification, N-t-Boc-Gln-Ala-Arg-AMC at 100–200 µM in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) is a practical starting point. Monitor AMC release at Ex/Em 360/460 nm.

What buffer conditions should I use for a Polyserase-2 fluorometric kinetics assay?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with direct use in activity assays after a simple dilution step to reduce glycerol below 1% (v/v) in the final reaction volume. Glycerol above ~2% can suppress fluorogenic substrate turnover. Maintain pH 7.5 and include 0.01% BSA or 0.01% Tween-20 to minimize surface adsorption at low enzyme concentrations. Polyserase-2 is a serine protease; include a PMSF or AEBSF negative-control condition to confirm on-target activity and distinguish from any contaminating protease activity.

What starting concentration of recombinant Polyserase-2 should I use in an inhibitor IC50 assay?

For a fluorometric IC50 assay, begin with 1–5 nM recombinant Polyserase-2 in a 100 µL reaction volume, using N-t-Boc-Gln-Ala-Arg-AMC at a substrate concentration bracketing your estimated Km (typically 50–200 µM for Arg-AMC substrates). Confirm that enzyme concentration is within the linear range of signal generation before running compound dose-responses. The protein is supplied at >90% purity by SDS-PAGE and <0.1 EU/µg endotoxin, so LPS interference in cell-based counter-screens is not a primary concern at these concentrations.

How much recombinant Polyserase-2 should I load as a positive control for Western blot?

Load 50–200 ng per lane as a positive control alongside your lysate samples. At 100 ng, the band at ~110–130 kDa (apparent MW, glycosylated) is reliably detected with RP-Polyserase2 (our matched rabbit polyclonal antibody, /anti-polyserase-2-rabbit-polyclonal-antibody) at a 1:500–1:2000 dilution. Because the recombinant runs above the predicted 95 kDa due to glycosylation, annotate this clearly in figure legends to avoid reviewer confusion. Use reducing conditions to collapse any disulfide-linked species to a single predominant band.

Can I use recombinant Polyserase-2 as a positive control when validating the RP-Polyserase2 rabbit polyclonal antibody?

Yes, and this is the intended paired use. REC-Polyserase2 and RP-Polyserase2 are produced in the same lab and validated together for Western blot. Load 50–200 ng of the recombinant alongside cell or tissue lysates known to express PRSS36. The recombinant provides an unambiguous positive-control band to confirm antibody specificity and appropriate molecular weight, which is especially useful when endogenous expression in your cell line is low or uncertain. RP-Polyserase2 is also validated for IHC, where the recombinant can serve as a spike-in control in solution-phase blocking experiments.

How should I store and handle recombinant Polyserase-2 to preserve enzymatic activity long-term?

Store at -20°C in single-use aliquots immediately upon receipt. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) stabilizes activity during frozen storage; the glycerol prevents freeze-concentration damage. Avoid repeated freeze-thaw cycles — each cycle can cause measurable loss of specific activity in serine proteases. For working dilutions, prepare fresh in assay buffer on ice and use within 4–8 hours. Do not dilute to below ~0.1 µg/mL without a carrier protein (0.1% BSA), as adsorptive losses to tube walls become significant at very low concentrations.

Validation imagery coming soon

Western blot validation figures for REC-Polyserase2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →